Plus Therapeutics appoints Kyle Guse to board; Greg Petersen resigns

PLUS THERAPEUTICS, INC.

Kyle Guse appointed to board effective April 18, 2025, filling vacancy from Greg Petersen's resignation.
Guse named to Audit Committee (Chair) and Compensation Committee; board deemed independent under Nasdaq rules.
Greg Petersen resigned same day; no disagreement with company operations, policies, or practices.
Guse is Chief Legal Officer at DDC Enterprise; previously CFO/GC at Atossa Therapeutics.
Guse brings 30 years of experience in finance, corporate governance, and M&A; will stand for reelection.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Greg Petersen

Director

PSTV · PLUS THERAPEUTICS, INC.

Effective: 2025-04-18
Successor: Kyle Guse
Filed: April 18, 2025, 7:59 PM ET

On April 18, 2025, Mr. Greg Petersen resigned as a member of the Board. Mr. Petersen informed the Company that his resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Appointed

Kyle Guse

Director

PSTV · PLUS THERAPEUTICS, INC.

Effective: 2025-04-18
Filed: April 18, 2025, 7:59 PM ET

On April 18, 2025, the Board of Directors (the “Board”) of Plus Therapeutics, Inc (the “Company”) unanimously appointed Mr. Kyle Guse to serve as a director of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Greg Petersen resigned as Director at PLUS THERAPEUTICS, INC..

Action: resigned
Role: Director

Exact text from the filing

On April 18, 2025, Mr. Greg Petersen resigned as a member of the Board. Mr. Petersen informed the Company that his resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kyle Guse was appointed as Director at PLUS THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

On April 18, 2025, the Board of Directors (the “Board”) of Plus Therapeutics, Inc (the “Company”) unanimously appointed Mr. Kyle Guse to serve as a director of the Board, effective immediately.

View on SEC.gov

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-055883

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.